Sélectionner une page


We are a preclinical-stage biotechnology company pioneering the development of engineered dendritic cell therapies for cancer treatment.

At EVIR Therapeutics, we use a new class of gene-modified dendritic cells to activate the immune system against cancer.

Unique among cell therapy strategies, our proprietary technology does not require a priori knowledge of tumor antigens.